Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 458-468 , April 2008

Transplantation in Remission Improves the Disease-Free Survival of Patients with Advanced Myelodysplastic Syndromes Treated with Myeloablative T Cell-Depleted Stem Cell Transplants from HLA-Identical Siblings

  • Hugo Castro-Malaspina

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationCorrespondence and reprint requests: Hugo Castro-Malaspina, MD, Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. Phone: (212) 639-8197. Fax: (212) 717-3371.
    • ,
  • Ann A. Jabubowski

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Esperanza B. Papadopoulos

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Farid Boulad

      Affiliations

    • Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • James W. Young

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Nancy A. Kernan

      Affiliations

    • Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Miguel A. Perales

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Trudy N. Small

      Affiliations

    • Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Katharine Hsu

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Michelle Chiu

      Affiliations

    • Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Glenn Heller

      Affiliations

    • Department of Epidemiology and Statistics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Nancy H. Collins

      Affiliations

    • Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Suresh C. Jhanwar

      Affiliations

    • Cytogenetics Laboratory, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Marcel van den Brink

      Affiliations

    • The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Stephen D. Nimer

      Affiliations

    • Hematology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Richard J. O'Reilly

      Affiliations

    • Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY

References 

  1. Appelbaum FR, Storb R, Ramberg RE, et al. Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Medic. 1984;100:689–693
  2. Appelbaum FR, Storb R, Ramberg RE, et al. Treatment of preleukemic syndromes with marrow transplantation. Blood. 1987;69:92–96
  3. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677–681
  4. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004
  5. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcome analysis according to IPSS score. Leukemia. 1998;(Suppl. 1):S25–S29
  6. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long term study of 71 patients. Blood. 1996;88:358–365
  7. Runde V, De Witte T, Gratwohl A, et al. Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant. 1998;21:255–261
  8. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimen and analysis of prognostic factors. Blood. 1996;87:51–58
  9. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndromes with advanced morphology: a phase II study of busulfan, cyclophosphamide and total body irradiation and analysis of prognostic factors. J Clin Oncol. 1996;14:220–226
  10. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and total body irradiation is associated with low relapse mortality but considerable non-relapse mortality. Biol Blood Marrow Transplant. 2002;8:161–169
  11. Demuynck H, Verhoef GEG, Zachee P, et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA identical siblings and alternative donors. Bone Marrow Transplant. 1996;17:745–751
  12. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110:620–630
  13. de Witte T, Suciu S, Verhoef G. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDS) and acute leukemia following MDS. Blood. 2001;98:2326–2331
  14. Yakoub-Agha I, De la Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a long-term study of 70 patients. Report of the French Society of Bone Marrow Transplantation. J Clin Oncol. 2000;18:963–971
  15. Scott BL, Storer B, Loken MR, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11:65–73
  16. Kernan NA, Bordignon C, Heller G, et al. Graft failure after T cell-depleted human leukocyte antigen identical marrow transplants for leukemia. I. Analysis of factors and results of secondary transplants. Blood. 1989;74:2227–2236
  17. Bordignon C, Keever CA, Small TN, et al. Graft failure after T cell depleted human leukocyte antigen identical marrow transplants for leukemia. II. In vitro analysis of host effector mechanisms. Blood. 1989;74:2237–2243
  18. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-vs-leukemia from graft-vs-host disease. Blood. 1995;86:1261–1268
  19. Young JW, Papadopoulos EB, Cunningham I, et al. T cell depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood. 1992;91:1083–1090
  20. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T cell depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998;91:1083–1090
  21. Benneth JM. World Health Organization classification of acute leukemias and myelodysplastic syndromes. Int J Hematol. 2000;72:131–133
  22. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  23. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcome, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642–4649
  24. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425
  25. Shank B, Chu FCH, Dinsmore R, et al. Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys. 1983;9:1607–1611
  26. Collins NH, Bleau SA, Kernan NA, O'Reilly RJ. T cell depletion of bone marrow by treatment with soybean agglutinin and sheep red blood cell rossetting. In:  Areman HJ,  Deeg HJ,  Sacher RA editor. Bone marrow and stem cell processing: a manual of current techniques. Philadelphia, PA: FA Davis; 1992;p. 171
  27. Collins NH, Fernandez JM, Bleau S, et al. Comparison of bone marrow and G-CSF mobilized peripheral blood progenitors from single normal donors before and after T cell depletion. Cytotherapy. 1999;1:223
  28. Small TN, Avigan D, Dupont B, et al. Immune reconstitution following T cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant. 1997;3:65–75
  29. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–864
  30. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–394
  31. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host disease syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  32. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  33. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  34. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  35. Cox DR. Regression models and life table analysis (with discussions), Series B. J Royal Stat Soc B. 1972;34:187–220
  36. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics. 1988;16:1141–1154
  37. Mattijssen V, Schattenberg A, Schaap N, et al. Outcome of allogeneic bone marrow transplantation with lymphocyte depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant. 1997;19:791–794
  38. de Witte T, Oosterveld M, Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndromes. Blood Reviews. 2006;21:49–59
  39. Deeg HJ, Shulman M, Anderson JE, et al. allogenic and syngeneic marrow transplantation for myelodysplastic syndromes in patients 55 to 66 years old. Blood. 2000;95:1188–1194
  40. Guardiola P, Runde V, Bacigalupo A, et al. Retrospective comparison of bone marrow and granulocyte colony stimulating factor mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2002;99:4370–4378
  41. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864
  42. Solomon SR, Savani BN, Childs R, et al. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11:619–626
  43. Alyea EP, kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:1047–1055
  44. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–339
  45. Hsu KC, Keever-Taylor CA, Wilson A, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005;105:4878–4884
  46. Castro-Malaspina H, Harris RH, Gajewski J. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis of 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943–1951
  47. Martino R, Caballero MD, Perez Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100:2243–2245
  48. de Lima M, Anagnostopoulos A, Munsell M, et al. Non-ablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  49. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem transplantation in AML and MDS using myeloablative versus reduced intensity conditioning: the role of dose intensity. Leukemia. 2006;20:322–328
  50. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs non-myeloablative allogeneic transplantation for patients with myelodysplastic syndrome and acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia. 2006;20:128–135
  51. Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846
  52. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  53. Porter DL, Roth MS, Lee SJ. Adoptive immunotherapy with donor mononuclear cells infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;18:975–980
  54. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  55. Depil S, Deconinck E, Milpied N, et al. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome. Bone Marrow Transplant. 2004;33:531–534
  56. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–3079
  57. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (WT1) mRNA in acute myeloid leukemias are associated with a worse long term treatment. Blood. 1997;90:1217–1225
  58. Patmasirivat P, Frazier G, Kantarjian H, et al. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia. 1999;891–900
  59. van Dyjk JP, Knops GHJ, van de Locht LTF, et al. Abnormal WT1 expression in the CD-34 negative compartment in myelodysplastic bone marrow. Brit J Haematol. 2002;118:1027–1033
  60. Oka Y, Elisseeva OA, Tsboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor gene (WT1) product. Immunogenetics. 2000;51:99–107
  61. Oka Y, Tsboi A, Taguchi T, et al. Induction of WT1 (Wilms tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resulting cancer regression. Proc Nat Acad Sci. 2004;101:13885–13890
  62. Jakubowski AA, Small TN, Young J, et al. Sustained engraftment and improved reconstitution: results of HLA-matched related, T cell depleted peripheral blood stem cell transplantation for adults with hematologic malignancies without the use of anti-thymocyte globulin. Blood. 2007;110:4552–4559
  63. Bolotin E, Smogorzewska M, Smith S, et al. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood. 1999;88:1887–1894
  64. Fry TJ, Christensen BL, Komschlies KL, et al. Interleukin 7 restores immunity in athymic T cell depleted hosts. Blood. 2001;97:1525–1533
  65. Mackall CL, Fry TJ, Bare G, et al. IL-& increases both thymic-dependent and thymic-independent T cell regeneration after bone marrow transplantation. Blood. 2001;97:1491–1497
  66. Alpdogan O, Schamaltaz C, Muriglan SJ, et al. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001;98:2256–2265
  67. Alpdogan O, Muriglan SJ, Eng JM, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003;112:1095–1107
  68. Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T cell reconstitution after bone marrow transplantation. Blood. 2002;99:4592–4600
  69. Rossi S, Blazar BR, Farrell CL, et al. Keratonocyte growth factor preserves normal thymopoieis and thymic microenvironment during experimental graft-verus-host disease. Blood. 2002;100:682–691
  70. Alpdogan O, Hubbard VM, Smith OM, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood. 2006;107:2453–2460
  71. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after fludarabine/busulfan based reduced intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82:336–342
  72. Kroger N, Shimoni A, Zabelina T, et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogenic stem cel transplantation in elderly patients with secondary acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant. 2006;37:339–344
  73. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulfan and alemtuzumab conditioning. Blood. 2004;104:1616–1623
  74. van Biesen K, Artz A, Smith S, et al. Fludarabine, melphalan and alemtuzumab conditioning in adults with standard-risk advanced myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728–5738
  75. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem cell transplantation using a reduced intensity conditioning regimen that has the capacity to produce durable remission and long term disease free survival in patients with high risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–9393

PII: S1083-8791(08)00069-4

doi: 10.1016/j.bbmt.2008.02.006

Biology of Blood and Marrow Transplantation
Volume 14, Issue 4 , Pages 458-468 , April 2008

Article Tools

* Image Usage & Resolution